Skip to main content
Top
Published in: Journal of Neuro-Oncology 2/2010

01-01-2010 | Clinical Study - Patient Study

Assessment of tumor angiogenesis as a prognostic factor of survival in patients with oligodendroglioma

Authors: H. Quon, A. Hasbini, J. Cougnard, L. Djafari, C. Lacroix, B. Abdulkarim

Published in: Journal of Neuro-Oncology | Issue 2/2010

Login to get access

Abstract

According to World Health Organization (WHO) and Daumas-Duport grading systems, progression of oligodendrogliomas (ODGs) to a higher grade (WHO grade III, grade B) is associated with increased angiogenesis. Based on multivariate assessment of molecular, pathological, and radiological parameters, we further assessed the influence of tumor angiogenesis on tumor progression and patient survival. Patients with a diagnosis of ODG, consecutively treated in a single institution, were reviewed and reclassified according to WHO and Daumas-Duport grading systems. MRI scans were reviewed to assess contrast enhancement and necrosis. Tissue sections were used for pathology review and to evaluate immunostaining of vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor (VEGF-R), Ki-67, and CD34. Multivariate analysis was performed to assess the impact of tumor angiogenesis-related pathological and radiological factors on patient survival. One hundred thirty-four patients with pure ODG were included in this study. Multivariate analysis identified four independent poor prognostic factors: necrosis, absence of seizure, increased vascularization, and age >55 years. A subgroup of patients with tumor necrosis, increased vascularization, and absence of seizures had a significantly worse outcome than predicted, with a median overall survival of 14.2 months. VEGF expression was significantly higher in this subgroup and correlated with disease progression regardless of histologic grade. Based on the presence of radiological or pathological necrosis, contrast enhancement or endothelial hyperplasia, and absence of seizures, a high risk group of ODG can be identified with significantly worse overall survival. Also, VEGF over-expression in ODG constitutes an early marker for predicting tumor progression.
Literature
1.
go back to reference Daumas-Duport C, Varlet P, Tucker ML et al (1997) Oligodendrogliomas. Part I: patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neurooncol 34:37–59CrossRefPubMed Daumas-Duport C, Varlet P, Tucker ML et al (1997) Oligodendrogliomas. Part I: patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neurooncol 34:37–59CrossRefPubMed
2.
go back to reference Shaw EG, Scheithauer BW, O’Fallon JR et al (1992) Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 76:428–434CrossRefPubMed Shaw EG, Scheithauer BW, O’Fallon JR et al (1992) Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 76:428–434CrossRefPubMed
3.
go back to reference Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK (eds). SEER Cancer Statistics Review, 1975–2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007 Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK (eds). SEER Cancer Statistics Review, 1975–2004, National Cancer Institute. Bethesda, MD, http://​seer.​cancer.​gov/​csr/​1975_​2004/​, based on November 2006 SEER data submission, posted to the SEER web site, 2007
4.
go back to reference Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714CrossRefPubMed Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714CrossRefPubMed
5.
go back to reference van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial. J Clin Oncol 24:2715–2722CrossRefPubMed van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial. J Clin Oncol 24:2715–2722CrossRefPubMed
6.
go back to reference Quon H, Abdulkarim B (2008) Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev, Issue 2. Art. No.: CD007104. DOI: 10.1002/14651858.CD007104 Quon H, Abdulkarim B (2008) Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev, Issue 2. Art. No.: CD007104. DOI: 10.​1002/​14651858.​CD007104
7.
go back to reference Schiffer D, Dutto A, Cavalla P et al (1999) Prognostic factors in oligodendroglioma. Can J Neurol Sci 24:313–319 Schiffer D, Dutto A, Cavalla P et al (1999) Prognostic factors in oligodendroglioma. Can J Neurol Sci 24:313–319
8.
go back to reference Saito A, Nakazato Y (1999) Evaluation of malignant features in oligodendroglial tumors. Clin Neuropathol 18:61–73PubMed Saito A, Nakazato Y (1999) Evaluation of malignant features in oligodendroglial tumors. Clin Neuropathol 18:61–73PubMed
9.
go back to reference Burger PC, Rawlings CE, Cox EB, McLendon RE, Schold SC Jr, Bullard DE (1987) Clinicopathologic correlations in the oligodendroglioma. Cancer 59:1345–1352CrossRefPubMed Burger PC, Rawlings CE, Cox EB, McLendon RE, Schold SC Jr, Bullard DE (1987) Clinicopathologic correlations in the oligodendroglioma. Cancer 59:1345–1352CrossRefPubMed
10.
go back to reference Celli P, Nofrone I, Palma L et al (1994) Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 35:1018–1034CrossRefPubMed Celli P, Nofrone I, Palma L et al (1994) Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 35:1018–1034CrossRefPubMed
11.
go back to reference Fortin D, Cairncross GJ, Hammond RR (1999) Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery 45:1279–1291CrossRefPubMed Fortin D, Cairncross GJ, Hammond RR (1999) Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery 45:1279–1291CrossRefPubMed
12.
go back to reference Giannini C, Scheithauer BW, Weaver AL et al (2001) Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 60:248–262PubMed Giannini C, Scheithauer BW, Weaver AL et al (2001) Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 60:248–262PubMed
13.
go back to reference Vaquero J, Zurita M, Morales C et al (2001) Prognostic significance of the endothelial surface in low-grade resected oligodendrogliomas. Br J Neurosurg 15:247–260CrossRefPubMed Vaquero J, Zurita M, Morales C et al (2001) Prognostic significance of the endothelial surface in low-grade resected oligodendrogliomas. Br J Neurosurg 15:247–260CrossRefPubMed
14.
go back to reference Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4–6CrossRefPubMed Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4–6CrossRefPubMed
15.
go back to reference Daumas-Duport C, Tucker ML, Kolles H et al (1997) Oligodendrogliomas. Part II: a new grading system based on morphological and imaging criteria. J Neurooncol 34:61–78CrossRefPubMed Daumas-Duport C, Tucker ML, Kolles H et al (1997) Oligodendrogliomas. Part II: a new grading system based on morphological and imaging criteria. J Neurooncol 34:61–78CrossRefPubMed
16.
go back to reference Brem S, Cotran R, Folkman J (1972) Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 48:347–356PubMed Brem S, Cotran R, Folkman J (1972) Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 48:347–356PubMed
17.
go back to reference Kleihues P, Cavenee WK, eds (2000). Pathology and genetics: tumors of the nervous system. In: WHO classification of tumors. Lyon (France): IARC press, 56–61 Kleihues P, Cavenee WK, eds (2000). Pathology and genetics: tumors of the nervous system. In: WHO classification of tumors. Lyon (France): IARC press, 56–61
18.
go back to reference Engelhard HH, Stelea A, Cochran EJ (2002) Oligodendroglioma: pathology and molecular biology. Surg Neurol 58:111–117CrossRefPubMed Engelhard HH, Stelea A, Cochran EJ (2002) Oligodendroglioma: pathology and molecular biology. Surg Neurol 58:111–117CrossRefPubMed
19.
go back to reference LeBlanc M, Crowley J (1992) Relative risk trees for censored survival data. Biometrics 48:411–425CrossRefPubMed LeBlanc M, Crowley J (1992) Relative risk trees for censored survival data. Biometrics 48:411–425CrossRefPubMed
20.
go back to reference Leighton C, Fisher B, Bauman G et al (1997) Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 15:1294–1301PubMed Leighton C, Fisher B, Bauman G et al (1997) Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 15:1294–1301PubMed
21.
go back to reference Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845–848CrossRefPubMed Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845–848CrossRefPubMed
22.
go back to reference Miller CR, Dunham CP, Scheithauer BW, Perry A (2006) Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 24(34):5419–5426CrossRefPubMed Miller CR, Dunham CP, Scheithauer BW, Perry A (2006) Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 24(34):5419–5426CrossRefPubMed
23.
go back to reference Kouwenhoven MC, Gorlia T, Kros J, et al. (2009). Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro-oncology. 2009 February 17 Kouwenhoven MC, Gorlia T, Kros J, et al. (2009). Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro-oncology. 2009 February 17
24.
go back to reference Bigner SH, Matthews MR, Rasheed BK et al (1999) Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 155:375–386PubMed Bigner SH, Matthews MR, Rasheed BK et al (1999) Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 155:375–386PubMed
25.
go back to reference Smith JS, Perry A, Borell TJ et al (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636–645PubMed Smith JS, Perry A, Borell TJ et al (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636–645PubMed
26.
go back to reference McDonald JM, See SJ, Tremont IW et al (2005) The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer 104:1468–1477CrossRefPubMed McDonald JM, See SJ, Tremont IW et al (2005) The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer 104:1468–1477CrossRefPubMed
27.
go back to reference Bortolotto S, Chiado-Piat L, Cavalla P et al (2000) CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas. Int J Cancer 88:554–567CrossRefPubMed Bortolotto S, Chiado-Piat L, Cavalla P et al (2000) CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas. Int J Cancer 88:554–567CrossRefPubMed
28.
go back to reference Perry A, Aldape KD, George DH, Burger PC (2004) Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendrogliomas. Cancer 101:2318–2326CrossRefPubMed Perry A, Aldape KD, George DH, Burger PC (2004) Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendrogliomas. Cancer 101:2318–2326CrossRefPubMed
29.
go back to reference Chan AS, Leung SY, Wong MP et al (1998) Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am J Surg Pathol 22:816–826CrossRefPubMed Chan AS, Leung SY, Wong MP et al (1998) Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am J Surg Pathol 22:816–826CrossRefPubMed
30.
go back to reference Abdulrauf SI, Edvardsen K, Ho KL et al (1998) Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg 88:513–520CrossRefPubMed Abdulrauf SI, Edvardsen K, Ho KL et al (1998) Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg 88:513–520CrossRefPubMed
31.
go back to reference Pietsch T, Valter MM, Wolf HK et al (1997) Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol 93:109–117CrossRefPubMed Pietsch T, Valter MM, Wolf HK et al (1997) Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol 93:109–117CrossRefPubMed
32.
go back to reference Christov C, Adle-Biassette H, Le Guerinel C et al (1998) Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the vasculature of oligodendrogliomas. Neuropathol Appl Neurobiol 24:29–35CrossRefPubMed Christov C, Adle-Biassette H, Le Guerinel C et al (1998) Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the vasculature of oligodendrogliomas. Neuropathol Appl Neurobiol 24:29–35CrossRefPubMed
33.
go back to reference Godfraind C, Rousseau E, Ruchoux MM et al (2003) Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas. Neuropathol Appl Neurobiol 29:462–471CrossRefPubMed Godfraind C, Rousseau E, Ruchoux MM et al (2003) Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas. Neuropathol Appl Neurobiol 29:462–471CrossRefPubMed
34.
go back to reference Harada H, Nakagawa K, Iwata S et al (1999) Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res 59:3783–3789PubMed Harada H, Nakagawa K, Iwata S et al (1999) Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res 59:3783–3789PubMed
35.
go back to reference Jen J, Harper JW, Bigner SH et al (1994) Deletion of p16 and p15 genes in brain tumors. Cancer Res 54:6353–6358PubMed Jen J, Harper JW, Bigner SH et al (1994) Deletion of p16 and p15 genes in brain tumors. Cancer Res 54:6353–6358PubMed
36.
go back to reference Varlet P, Guillamo JS, Nataf F et al (2000) Vascular endothelial growth factor expression in oligodendrogliomas: a correlative study with Sainte-Anne malignancy grade, growth fraction and patient survival. Neuropathol Appl Neurobiol 26:379–389CrossRefPubMed Varlet P, Guillamo JS, Nataf F et al (2000) Vascular endothelial growth factor expression in oligodendrogliomas: a correlative study with Sainte-Anne malignancy grade, growth fraction and patient survival. Neuropathol Appl Neurobiol 26:379–389CrossRefPubMed
37.
go back to reference Louis DN, Holland EC, Cairncross JG (2001) Glioma classification: a molecular reappraisal. Am J Pathol 159:779–786PubMed Louis DN, Holland EC, Cairncross JG (2001) Glioma classification: a molecular reappraisal. Am J Pathol 159:779–786PubMed
38.
go back to reference Reifenberger J, Reifenberger G, Liu L et al (1994) Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145:1175–1190PubMed Reifenberger J, Reifenberger G, Liu L et al (1994) Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145:1175–1190PubMed
39.
go back to reference Burger PC, Minn AY, Smith JS et al (2001) Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol 14:842–853CrossRefPubMed Burger PC, Minn AY, Smith JS et al (2001) Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol 14:842–853CrossRefPubMed
40.
go back to reference Cairncross JG, Ueki K, Zlatescu MC et al (1999) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479CrossRef Cairncross JG, Ueki K, Zlatescu MC et al (1999) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479CrossRef
41.
go back to reference Thiessen B, Maguire JA, McNeil K et al (2003) Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. J Neurooncol 64:271–278CrossRefPubMed Thiessen B, Maguire JA, McNeil K et al (2003) Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. J Neurooncol 64:271–278CrossRefPubMed
42.
go back to reference Hashimoto N, Murakami M, Takahashi Y et al (2003) Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p. Cancer 97:2254–2261CrossRefPubMed Hashimoto N, Murakami M, Takahashi Y et al (2003) Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p. Cancer 97:2254–2261CrossRefPubMed
Metadata
Title
Assessment of tumor angiogenesis as a prognostic factor of survival in patients with oligodendroglioma
Authors
H. Quon
A. Hasbini
J. Cougnard
L. Djafari
C. Lacroix
B. Abdulkarim
Publication date
01-01-2010
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 2/2010
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-009-9961-x

Other articles of this Issue 2/2010

Journal of Neuro-Oncology 2/2010 Go to the issue

Laboratory Investigation - Human/Animal Tissue

A survey of glioblastoma genomic amplifications and deletions